Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XcelerateXCRT +11.02% EV-to-FCF is 90.16 as of Sep. 18, 2026. The stock has 4 warning signs investors should review. Among 421 Healthcare Providers & Services companies, Xcelerate ranks worse than 90.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xcelerate's Enterprise Value is $9.92 Mil.
Xcelerate's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $0.11 Mil. Therefore, Xcelerate's EV-to-FCF for today is 90.16.
The historical rank and industry rank for Xcelerate's EV-to-FCF or its related term are showing as below:
XCRT'
s EV-to-FCF Range Over the Past 10 Years
Min: -91.9 Med: -47.57 Max: 123.72
Current: 91.83
During the past 13 years, the highest EV-to-FCF of Xcelerate was 123.72. The lowest was -91.90. And the median was -47.57.
XCRT's EV-to-FCF is ranked worse than 90.74% of 421
companies
in the Healthcare Providers & Services industry
Industry Median: 17.29
vs XCRT: 91.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xcelerate's share price for today is $0.01998.
Xcelerate's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xcelerate EV-to-FCF Related Terms
Xcelerate EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Xcelerate's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Xcelerate's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xcelerate EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Xcelerate's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xcelerate's EV-to-FCF falls into.
Xcelerate's current Enterprise Value is $9.92 Mil.
Xcelerate's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xcelerate (XCRT) has a EV-to-FCF of 90.16 as of Sep. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xcelerate and its competitors. According to the industry distribution chart, Xcelerate ranks #382 out of 421 companies in the Healthcare Providers & Services industry, placing it in the top 90.7%.
Is Xcelerate's EV-to-FCF too high?
Xcelerate's current EV-to-FCF is 90.16. The Healthcare Providers & Services industry median EV-to-FCF is 17.29. Xcelerate's value of 90.16 is 421.5% above this industry median. Based on the distribution chart, Xcelerate ranks #382 out of 421 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Xcelerate's EV-to-FCF compare to VLXC and RHEP?
According to the Healthcare Providers & Services industry distribution chart, Xcelerate ranks #382 out of 421 companies for EV-to-FCF. This places Xcelerate in the lower half of its industry. The industry median EV-to-FCF is 17.29. Xcelerate's value of 90.16 is 421.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.29, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xcelerate's current EV-to-FCF of 90.16 is 421.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xcelerate and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xcelerate's current EV-to-FCF is 90.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xcelerate stock overvalued right now?
Xcelerate (XCRT) has a current EV-to-FCF of 90.16. The current EV-to-FCF is 90.16 and 421.5% above the Healthcare Providers & Services industry median of 17.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Xcelerate (XCRT), the current EV-to-FCF is 90.16 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xcelerate Inc is a healthcare services and products company engaged in three separate but related businesses within the medical, health, and wellness sectors. It is focused on the development of medical technology and the provision of virtual health services to help patients in developing countries meet their medical needs by extending the reach of physicians through technology. The company is also involved in the formulation, packaging, and marketing of consumer health and beauty, clinically tested skin and hair care products, and owns and licenses the rights to various forms of medical equipment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCRT has been successfully added to your 
